Market by Device Type, Route of Administration, End-user, and Country | Forecast 2019-2028
Triton’s research on the Europe injectable drug delivery market depicts that it will grow at a CAGR of 8.22% in terms of revenue during the forecast period 2019-2028.
Report scope can be customized per your requirements. Request For Customization
The countries analyzed in this market include:
• The UK
• France
• Germany
• Russia
• Spain
• Italy
• Rest of Europe countries
The rise in the prevalence of cancer and chronic diseases like CVDs is mainly driving the market for injectable drug delivery systems in the United Kingdom. Statistics from Cancer Research UK indicate that, in 2015, were around 360,000 new cases of cancer were detected in the country’s population. Further, according to the British Heart Foundation, CVDs, are responsible for 160,000 deaths annually in the UK, accounting for 26% of all deaths. It states that, in 2017, there were around 7 million individuals in the country living with cardiovascular diseases.
The alarming rise in the occurrence of these conditions has called for the adoption of devices and treatments to enhance the quality of life of patients. It is necessary to deliver these treatments appropriately and safely to patients for better results. Therefore, there is an increased demand for injectable drug delivery systems in the country, which is aiding the growth of its injectable drug delivery market over the forecast period.
As per the WHO, chronic diseases account for a staggering 93% of the deaths in Germany. It also estimates the prevalence of obesity to increase rapidly over the coming years. Large-molecule IV biologics for treating chronic diseases, delivered in prefilled formats, are being used for frequent drug administration. This is raising the adoption of injectable drug delivery systems in the country, leading to increased market penetration. Thus, the growing prevalence of chronic diseases is helping the German market to flourish over the coming years.
Novo Nordisk A/S provides products for obesity and diabetes acre. It is one of the leaders in the field of hormone replacement therapy, growth hormone therapy, and hemophilia. With its headquarters in Bagsvaerd, Denmark, the company operates across several countries in Europe as well as other regions.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. EUROPE INJECTABLE DRUG DELIVERY MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. PORTER’S FIVE FORCES MODEL
2.2.1. THREAT OF NEW ENTRANT
2.2.2. THREAT OF SUBSTITUTE
2.2.3. BARGAINING POWER OF BUYERS
2.2.4. BARGAINING POWER OF SUPPLIERS
2.2.5. INTENSITY OF COMPETITIVE RIVALRY
2.3. KEY INSIGHT
2.4. KEY BUYING CRITERIA
2.5. MARKET ATTRACTIVENESS INDEX
2.6. MARKET DRIVERS
2.6.1. INCREASING GERIATRIC POPULATION
2.6.2. TECHNOLOGICAL ADVANCEMENT
2.6.3. GROWING OCCURRENCE OF AUTOIMMUNE DISEASES
2.7. MARKET RESTRAINTS
2.7.1. HIGH MANUFACTURING COST OF INJECTABLE DRUG DELIVERY SYSTEMS
2.8. MARKET OPPORTUNITIES
2.8.1. DEVELOPMENT OF BETTER INJECTABLE SYSTEMS
2.8.2. INCREASE IN HEALTHCARE EXPENDITURE
2.9. MARKET CHALLENGES
2.9.1. DEVELOPMENTS IN ALTERNATE DRUG DELIVERY SYSTEMS
2.9.2. STRINGENT REGULATIONS
3. INJECTABLE DRUG DELIVERY MARKET OUTLOOK - BY DEVICE TYPE
3.1. PEN INJECTOR
3.2. AUTO-INJECTOR
3.3. NEEDLE-FREE INJECTOR
3.4. PREFILLED SYRINGE
4. INJECTABLE DRUG DELIVERY MARKET OUTLOOK - BY ROUTE OF ADMINISTRATION
4.1. SUBCUTANEOUS
4.2. INTRAMUSCULAR
4.3. INTRAVENOUS (IV)
4.4. OTHER ROUTE OF ADMINISTRATION
5. INJECTABLE DRUG DELIVERY MARKET OUTLOOK - BY END-USER
5.1. CLINICS/ PHYSICIAN OFFICES
5.2. AMBULATORY CARE
5.3. HOSPITAL
5.4. HOME-BASED
5.5. OTHER END-USERS
6. INJECTABLE DRUG DELIVERY MARKET – EUROPE
6.1. COUNTRY ANALYSIS
6.1.1. UNITED KINGDOM
6.1.2. GERMANY
6.1.3. FRANCE
6.1.4. ITALY
6.1.5. SPAIN
6.1.6. RUSSIA
6.1.7. REST OF EUROPE
7. COMPANY PROFILES
7.1. BAXTER INTERNATIONAL INC
7.2. BECTON DICKINSON AND COMPANY (BD)
7.3. ELCAM MEDICAL
7.4. ELI LILLY AND COMPANY
7.5. GERRESHEIMER
7.6. INJEX
7.7. NOVARTIS AG
7.8. NOVO NORDISK A/S
7.9. PFIZER INC
7.10. SANOFI SA
7.11. SCHOTT AG
7.12. TERUMO CORPORATION
7.13. TEVA PHARMACEUTICALS
7.14. WEST PHARMACEUTICALS
7.15. YPSOMED HOLDING AG
8. RESEARCH METHODOLOGY & SCOPE
8.1. RESEARCH SCOPE & DELIVERABLES
8.1.1. OBJECTIVES OF STUDY
8.1.2. SCOPE OF STUDY
8.2. SOURCES OF DATA
8.2.1. PRIMARY DATA SOURCES
8.2.2. SECONDARY DATA SOURCES
8.3. RESEARCH METHODOLOGY
8.3.1. EVALUATION OF PROPOSED MARKET
8.3.2. IDENTIFICATION OF DATA SOURCES
8.3.3. ASSESSMENT OF MARKET DETERMINANTS
8.3.4. DATA COLLECTION
8.3.5. DATA VALIDATION & ANALYSIS
TABLE 1 EUROPE INJECTABLE DRUG DELIVERY MARKET, BY REGION, 2019-2028 ($ MILLION)
TABLE 2 EUROPE INJECTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2019-2028 ($ MILLION)
TABLE 3 DIFFERENT TYPES OF INSULIN PEN INJECTORS
TABLE 4 MARKETED NEEDLE-FREE INJECTORS PRODUCTS
TABLE 5 LYOPHILIZED DRUGS WHICH ARE USED IN PREFILLED SYRINGE
TABLE 6 EUROPE INJECTABLE DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 ($ MILLION)
TABLE 7 EUROPE INJECTABLE DRUG DELIVERY MARKET, BY END-USER, 2019-2028 ($ MILLION)
TABLE 8 EUROPE INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019-2028 ($ MILLION)
FIGURE 1 EUROPE INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 2 KEY BUYING IMPACT ANALYSIS
FIGURE 3 EUROPE INJECTABLE DRUG DELIVERY MARKET, BY PEN INJECTOR, 2019-2028 ($ MILLION)
FIGURE 4 EUROPE INJECTABLE DRUG DELIVERY MARKET, BY AUTO-INJECTOR, 2019-2028 ($ MILLION)
FIGURE 5 EUROPE INJECTABLE DRUG DELIVERY MARKET, BY NEEDLE-FREE INJECTOR, 2019-2028 ($ MILLION)
FIGURE 6 EUROPE INJECTABLE DRUG DELIVERY MARKET, BY PREFILLED, 2019-2028 ($ MILLION)
FIGURE 7 EUROPE INJECTABLE DRUG DELIVERY MARKET, BY SUBCUTANEOUS, 2019-2028 ($ MILLION)
FIGURE 8 EUROPE INJECTABLE DRUG DELIVERY MARKET, BY INTRAMUSCULAR, 2019-2028 ($ MILLION)
FIGURE 9 EUROPE INJECTABLE DRUG DELIVERY MARKET, BY INTRAVENOUS, 2019-2028 ($ MILLION)
FIGURE 10 EUROPE INJECTABLE DRUG DELIVERY MARKET, BY OTHER ROUTE OF ADMINISTRATION, 2019-2028 ($ MILLION)
FIGURE 11 EUROPE INJECTABLE DRUG DELIVERY MARKET, BY CLINICS/PHYSICIAN OFFICES, 2019-2028 ($ MILLION)
FIGURE 12 EUROPE INJECTABLE DRUG DELIVERY MARKET, BY AMBULATORY CARE, 2019-2028 ($ MILLION)
FIGURE 13 EUROPE INJECTABLE DRUG DELIVERY MARKET, BY HOSPITAL, 2019-2028 ($ MILLION)
FIGURE 14 EUROPE INJECTABLE DRUG DELIVERY MARKET, BY HOME-BASED, 2019-2028 ($ MILLION)
FIGURE 15 EUROPE INJECTABLE DRUG DELIVERY MARKET, BY OTHER END-USER, 2019-2028 ($ MILLION)
FIGURE 16 UNITED KINGDOM INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 17 GERMANY INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 18 FRANCE INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 19 ITALY INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 20 SPAIN INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 21 RUSSIA INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 22 REST OF EUROPE INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)